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ABSTRACT
Objective: Proton pump inhibitors (PPIs) are known to impair cytochrome P2C19 mediated activation of clopidogrel, the antiplatelet agent used 
for cardiovascular risk prevention. Esomeprazole is an optical isomer of omeprazole with better efficacy and tolerability than conventional PPIs. 
Esomeprazole is often co-administered with clopidogrel considering the risk of associated gastrointestinal bleeding. This study was designed to 
determine the effect of esomeprazole on the mean pharmacokinetic profile clopidogrel.
Methods: A total of 14 adult healthy male participants who volunteered participation were enrolled, randomized equally into two cross-over 
sequences, dosed with clopidogrel and clopidogrel + esomeprazole in respective periods. Blood samples were collected through antecubital or 
forearm vein indwelling catheter. Concentration of clopidogrel parent prodrug in isolated plasma was determined using validated sensitive liquid 
chromatography – mass spectrometry. Pharmacokinetic modeling was carried out using PKSOLVER add-in for Microsoft Excel.
Results: The pharmacokinetic profile of clopidogrel was non-significantly altered by esomeprazole. Statistically significant difference in peak 
plasma concentration, apparent volume of distribution, and clearance of clopidogrel was observed only during period II in participants co-dosed 
with esomeprazole (p=0.0483, 0.0011, and 0.0015, respectively). All other primary and secondary pharmacokinetic parameters displayed minor 
alterations during either period (p>0.05).
Conclusion: The non-significant alteration of clopidogrel pharmacokinetics by esomeprazole can be potentiated by underlying predisposing factors 
such as the presence of CYP2C19 allelic variants and increasing the risk of cardiovascular events. Hence, co-administration of clopidogrel and 
esomeprazole should be under clinical monitoring and is not recommended in poor responders of antiplatelet therapy with clopidogrel.
Keywords: Clopidogrel, CYP2C19, Esomeprazole, Enzyme inhibition, Pharmacokinetics.
INTRODUCTION
Clopidogrel is a platelet adenosine diphosphate receptor antagonist 
indicated for the prophylaxis of atherosclerotic events including 
myocardial infarction, ischemic stroke and vascular death manifested 
either by recent stroke, or established peripheral vascular disease [1]. 
It is a prodrug that requires a two-step oxidative biotransformation 
process for conversion into an inactive and active metabolite of 
clopidogrel (AMC) involving human carboxylesterase 1 and CYP450 
enzymes including CYP1A2, CYP2B6, CYP2C9, CYP2C19, and 
CYP3A4/5 [2,3]. Besides the implication of diverse CYP450 enzymes 
in clopidogrel activation, the role of CYP2C19 is prominent and well 
established [4]. Altered genetic patterns of CYP2C19 are associated 
with diminished platelet response to clopidogrel treatment and poor 
cardiovascular outcomes [5,6]. It has been reported that 4-30% of 
patients treated with clopidogrel do not display adequate therapeutic 
response, while about 10% of patients face unpleasant bleeding 
events [7]. Various drugs that are substrates or inhibitors of CYP2C19 
tend to significantly alter clopidogrel pharmacokinetics precipitating 
impaired therapeutic response [8,9]. Proton pump inhibitors 
(PPI) are a class of potential antiulcer agents used for providing 
rapid symptom relief and healing in patients with peptic ulcer and 
gastroesophageal reflux disease [10]. PPIs are often prescribed 
with clopidogrel and low dose aspirin to prevent gastrointestinal 
(GI) bleeding and ulcers. Concomitant use of PPIs substantially 
decreases the risk of upper GI bleeding in patients receiving low-dose 
aspirin (LDA) and clopidogrel [11]. However, being inhibitors of the 
microsomal enzyme system, conventional PPIs such as omeprazole 
alter the mean pharmacokinetic profile of clopidogrel [12,13]. Co-
administration of PPI and other CYP450 inhibitors with clopidogrel 
decreases AMC concentration with a parallel increase in the 
concentration of clopidogrel parent prodrug (CPP) magnifying the 
risk of cardiovascular events [14,15]. Esomeprazole is an optical 
isomer of omeprazole and is being broadly considered over other 
conventional PPIs owing to its high systemic bioavailability and 
prolonged duration of action [16]. In spite of retaining the CYP450 
enzyme inhibition property of its parent racemic omeprazole, the 
standard 40 mg dose of esomeprazole is being widely used due to 
a better pharmacodynamic response such as improved symptom 
resolution and mucosal healing [17,18]. This study was hence 
designed to study the effect of esomeprazole on the pharmacokinetic 
profile of clopidogrel. We considered CPP profiling over AMC owing 
to its chemical instability and low circulating levels which make 
quantification in plasma intricate [19].
METHODS
Study site and approval
This study was conducted for a period of 2 months in a tertiary 
care hospital. The protocol was reviewed and approved by the 
Institutional Ethics Committee before study commencement (Ref No.: 
IEC/RVSIMS/2017/04). Consent from the hospital authorities was 
obtained before using the clinical facilities and subject enrolment.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i7.18855
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Subject recruitment and confidentiality
Adult healthy male volunteers who were willing to participate were 
screened for factors that restrict their enrolment. All participants 
underwent a screening procedure comprising demographics, personal 
history, medical history, and clinical laboratory investigations before 
enrolment. The study protocol was explained to volunteer in his native 
language under the supervision of a registered medical practitioner. 
Participants were enrolled into the study only on provision of written 
informed consent. All data were documented in specially designed case 
report forms, and access was restricted to the investigator to ensure 
non-violation of subject rights and confidentiality.
Sample size
A total of 14 participants who met the inclusion criterion were enrolled 
into the study.
Study sequences and design
This randomized control study of 2 × 2 crossover design had two 
sequences on either period as shown in Table 1.
Inclusion criterion
•	 Healthy	human	male	participants	 in	 the	 age	 sequence	between	
18 and 55 years and body mass index (BMI) within the range of 





•	 Participants	 should	 not	 have	 consumed	 any	medication	 or	
furanocoumarin-containing fruit products 72 hrs before dosing and 
throughout the study periods.
Exclusion criterion
•	 Participants	with	history	of	 smoking,	 alcohol	 dependence,	 and	
alcohol abuse within the past 1 year
•	 Participants	with	history	of	abuse	with	amphetamines,	cocaine,	tetra	
hydro cannabinoids, benzodiazepines, barbiturates, and opioids 
within 1 year
•	 Participants	with	allergy	or	significant	history	of	hypersensitivity	or	
idiosyncratic reactions to clopidogrel or esomeprazole
•	 Participants	with	systolic	blood	pressure	(BP)	<100	and	>130	mmHg,	
diastolic pressure <60 and >80 mmHg and pulse rate <60 and 
>100 beats/min during screening
•	 Participants	with	history	of	dysphagia	or	difficulty	 in	coming	 for	
follow-up
•	 Participants	who	had	suffered	any	clinically	significant	illness	within	
1 month before study commencement
•	 Participants	diagnosed	with	ulceration	or	history	of	gastric	and/or	
duodenal ulcer during screening.
Sampling method
Blood samples were obtained from antecubital vein or forearm vein 
using an indwelling catheter. Heparin lock technique was used to 
prevent clotting of the indwelling catheter. After every blood sample 
collection, 0.5 ml of heparinized saline was injected into the intravenous 
cannula to prevent clot formation. 5 ml of blood sample was collected 
1 hr before dosing. 5 ml of post-dose blood samples were collected at 
the following time points (hours): 0.17, 0.33, 0.5, 0.67, 1.0, 1.5, 2.0, 3.0, 
6.0, 8.0, and 12.0. Mean±standard deviation (SD) loss of blood from 
each volunteer during the entire study was 130±5 ml. Blood samples 
were collected in pre-labeled serum separator vacutainers, containing 
tri potassium ethylenediaminetetraacetic acid as an anticoagulant.
Serum isolation and storage
Blood samples were centrifuged at 4000 rpm for 10 minutes at a 
mean±SD temperature of 4±2°C within 45 minutes of blood collection. 
The resulting plasma sample was separated into two aliquots and 
stored	in	pre-labeled	Eppendorf	tubes	at	−70°C	until	analysis.
Estimation of plasma clopidogrel concentrations
CPP in human plasma was determined using sensitive liquid 
chromatography – mass spectrometry (LC-MS) technique. Clopidogrel 
bisulfate and ticlopidine obtained as gift samples were used as working 
and internal standard, respectively. Thermo TSQ Quantum Ultra LC-MS 
system was used for determination. ZORBAX Eclipse Plus C18 column 
of 4.6 mm × 150 mm dimension and 5 µm diameter was employed. 
80:20% v/v acetonitrile: 10 mM ammonium acetate, respectively, was 
used as mobile phase. The column flow rate was 1 ml/min and injection 
volume of 10.0 µL. Protein precipitation technique was employed for 
extraction of the drug before loading into LC-MS. Four replicates of 
three different level quality control samples (high, medium, and low) 
were analyzed with each batch of subject samples.
Pharmacokinetic modeling
Peak plasma concentration (Cmax) and time taken to attain Cmax (tmax) were 
determined by visual inspection. Other pharmacokinetic parameters 
including t½, volume of distribution (Vd), clearance (Cl), area under the 
curve (AUC(0−t)), AUC(0−∞), area under mean curve (AUMC), and mean 
residence time (MRT) were calculated using PKSOLVER add-in for 
Microsoft Excel 2010. Pharmacokinetic parameters were based on the 
plasma concentration time using extravascular one-compartmental 
model.
Statistical analysis
Statistical analyses were performed using International Business 
Machines – Statistical Package for the Social Sciences (IBM – SPSS) 
20.0. Statistical significance of difference in population means between 
and within participants was assessed by independent two-sample and 
paired samples t-test, respectively. Descriptive summary statistics are 
presented either as mean±SD or as median (minimum and maximum). 
Choice of descriptive and inferential statistical method was based on 
distribution normality as determined through normal probability plot.
RESULTS
Demographics and clinical parameters
A total of 19 healthy male volunteers who expressed willingness to 
participate underwent screening. Five volunteers who did not meet the 
inclusion criterion were restricted participation. Age wise distribution 
of 14 participants enrolled into the study is shown in Table 2. The 
subject dropout rate was 0% as all participants turned for period II 
after a washout period and no subject withdrew before completion of 
the study during either period.
The mean±SD age of the participants was 33±5.53 years with an age 
range of 24-44 years. All participants displayed normal BMI with 
a mean±SD value of 22.4±1.1 kg/m2. Subject safety was monitored 
through clinical laboratory evaluations during screening and post-
intervention, vital sign measurements during pre-intervention and at 
pre-determined time points post-intervention. Significant difference 
was not observed between daily BP (p=0.471) and capillary blood 
glucose (p=0.092). However, statistically significant mean reduction 
was observed with red blood cells (RBC), hemoglobin, hematocrit 
and white blood cells (WBC), and platelets. In addition, statistically 
significant increase in serum creatinine was observed as shown in 
Table 3.






Esomeprazole + Clopidogrel 
(number of participants)
Period 1 7a 7b
Period 2 7b 7a
aParticipants dosed with clopidogrel in period I and both esomeprazole 
and clopidogrel in period II after a washout period of 15 days (Sequence I). 
bParticipants dosed with both esomeprazole and clopidogrel in period I and 
clopidogrel in period II after a washout period of 15 days (Sequence II)
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Bioanalytical parameters
The mean±SD retention times of clopidogrel and ticlopidine were 
approximately 1.59±0.5 and 1.77±0.5 minutes, respectively. The overall 
chromatography run time was 2.5 minutes. The total accuracy for the 
quality control samples of clopidogrel ranged from 97.13% to 101.59% 
with percentage coefficient of variation (%CV) ranging from 10.34% to 
14.10%. The calibration curve for clopidogrel is shown in Fig. 1.
y = 0.0002523x + 0.1292, correlation coefficient (r2) =0.9946
Intra-subject variability - Effect of esomeprazole on the 
pharmacokinetics of CPP
The mean pharmacokinetic profile of CPP was not found to be altered 
significantly by esomeprazole co-administration. Cmax of CPP was 
increased on esomeprazole administration in either sequence. However, 
the difference was statistically significant only in Sequence I as shown 
in Figs. 2 and 3. Similar period effects of V/F and CL/F observed in 
Sequence I was not observed in Sequence II. Mean intra-subject and 
inter-subject variability data for clopidogrel expressed as the mean 
%CV are also given in Tables 4 and 5.
Intra-subject variability for AUC(0−t), AUC(0−∞), and Cmax is 35.3%, 
32.8%, and 29.4%, respectively. Intra-subject variability for secondary 
parameters including tmax, Kel, t½ka, V/F, CL/F, AUMC, and MRT is 14.9%, 
18.9%, 14.9%, 30%, 32.8%, 35.9%, and 15.1%, respectively.
Inter-subject variability
Difference in pharmacokinetics of CPP was not observed between 
participants as shown in Figs. 4 and 5. Significant sequence effects 
of V/F and CL/F were observed during period II (p=0.0087 and 
0.0097, respectively). The %CV of inter-subject variability for primary 
pharmacokinetic parameters including AUC(0-t), AUC (0-∞), and Cmax are 
31.6%, 29.0%, and 20.6%, respectively. Inter-subject variability for 
Table 2: Summary of demographics
S.No. Parameter Frequency (N=14) Mean±SD
Range N (%)
1. Age (years) 18-35 8 (57.1) 29.2±3.3
36-50 6 (42.9) 29.2±3.3
2. Height (cm) 150-170 11 (78.6) 167.6±6.25
171-190 3 (21.4) 167.6±6.25
3. Mass (kg) 50-65 8 (57.1) 64.35±6.03
66-80 6 (42.9) 64.35±6.03
4. BMI (kg/m2) 18-25 14 (100) 22.4±1.1
BMI: Body mass index
Table 3: Comparison of predosing and endpoint biochemical parameters
S.No. Biochemical parameter Pre-intervention Post-intervention p values
1. RBC (million/mm3) 5.04±0.42 4.41±0.37 <0.0001*
2. Hemoglobin (g/dL) 13.65±1.06 13.14±1.0 0.0042*
3. Hematocrit (%) 43.35±2.14 38.21±2.08 <0.0001*
4. Total WBC count (cells/mm3) 8385.7±2469.4 6871.4±1572.7 0.0146**
5. Polymorphs (%) 58.07±5.22 57.92±7.95 0.9431
6. Lymphocytes (%) 32.07±6.04 35.71±7.76 0.0526
7. Eosinophils (%) 4.85±2.89 4.14±1.12 0.3889
8. Platelet (lakh cells/mm3) 259.5±56.5 2.57±0.57 <0.0001*
9. Random blood sugar (mg/dL) 89.14±12.97 95.57±10.21 0.2579
10. Blood urea nitrogen (mg/dL) 10±3.29 7.57±2.45 0.0702
11. Serum creatinine (mg/dL) 0.77±0.11 0.96±0.09 0.0001*
12. Bilirubin-total (mg/dL) 1.14±0.73 0.9±0.50 0.0447**
13. Bilirubin – Direct (mg/dL) 0.3±0.18 0.26±0.08 0.3356
14. Bilirubin – Indirect (mg/dL) 0.83±0.57 0.63±0.43 0.0538
15. SGOT (U/L) 39.21±55.20 23±10.53 0.3024
16. SGPT (U/L) 37.35±43.04 27.07±17.69 0.3722
*p<0.01, **p<0.05, p value obtained through paired Student’s t-test. SGOT: Serum glutamic-oxaloacetic transaminase, SGPT: Serum glutamic-pyruvic transaminase, 
RBC: Red blood cell, WBC: White blood cell
Fig. 1: Calibration curve for clopidogrel
Fig. 2: Intra-subject variability observed in Sequence I
secondary pharmacokinetic parameters including tmax, Kel, t½ka, V/F, 
CL/F, AUMC, and MRT is 16.4%, 23.6%, 25.0%, 26.8%, 29.0%, 31.7%, 
and 15.8%, respectively.
DISCUSSION
Clopidogrel and LDA are often combined with PPIs considering 
the associated risk of GI ulceration and bleeding. Despite the well-
established potential to interact with clopidogrel through major CYP2C19 
inhibition, PPI’s cannot be replaced with histamine receptor antagonists 
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(H2RA) as they are associated with risk of mucosal erosion in patients 
receiving antiplatelet therapy [20]. Therefore, it is crucial to identify 
PPIs with optimal enzyme inhibition property and high potency to 
prevent GI events in patients receiving clopidogrel, as non-adherence to 
antiplatelet agents develops after experiencing GI bleeding potentiating 
the risk of ischemic events [21]. In addition, the risk of cardiovascular 
events is precipitated by factors that impair production of AMC from 
CPP. Concentrations of CPP and AMC are known to be altered by 
several patient specific variables including demographics, personal and 
medical history, organ function, and concomitant medication [22-24]. 
To avoid variability arising due to gender and considering the risk 
of comparatively higher predisposition to adverse drug reactions, 
women volunteers were not enrolled into the study [25,26]. Although 
CYP2C19 activity is equal in both men and women, other factors such 
as higher gastric pH, gastric-bowel transit times, and altered Vd in 
women can cause variability in pharmacokinetics [27]. Bioavailability 
of clopidogrel active metabolite has been reported to be less in 
patients with higher body weight contributing to suboptimal treatment 
response [28]. Hence, to dodge the bias arising due to body weight, only 
participants with normal BMI (18.5-24.9 kg/m2) were enrolled into 
the study. Volunteers with any other demographic factor, personal, and 
medical history that may impair the results of the study were limited 
participation. Clinical laboratory investigations were carried out 
pre- and post-intervention to ensure subject safety. A gross decrease 
in hematological parameters including RBC, hemoglobin, WBC platelets 
was observed at the study end point. Although they did not manifest 
as adverse hematological reactions, the changes in parameters were 
statistically significant. However, diverse hematological adverse effects 
such as anemia, agranulocytosis, leukopenia, and thrombocytopenia 
have been reported in patients receiving clopidogrel or LDA [29]. 
AMC is extensively protein bound (94%) and hence minor change in 
plasma concentration would exert considerable effects on inhibition 
of platelet aggregation [30,31]. The pharmacologically active form of 
clopidogrel is clopidogrel thiol or AMC. Clopidogrel thiol is chemically 
unstable and has low circulating levels which make its determination 
in any biological matrix problematic [15]. Hence, we quantified CPP 
since a decrease in AMC is often accompanied by a parallel increase 
in CPP. Thus, considering the possible inverse relationship between 
CPP and AMC, CPP profiling was used as an indirect measure of AMC 
pharmacokinetics.
PPIs are well known to alter the pharmacokinetics of clopidogrel by 
impairing prodrug activation. We herein report insignificant alteration 
of CPP pharmacokinetics by esomeprazole. Although insignificant, 
Fig. 3: Intra-subject variability in Sequence II
Table 4: Effect of esomeprazole on CPP pharmacokinetics in Sequence I participants
S.No. PK parameter (Mean±SD) %CV p value
Period 1C Period 2EC
1. t1/2ka* 0.51±0.03 0.434±0.15 15.0 0.6034
2. V/F 0.05±0.00 0.0196±0.00 42.0 0.0011
3. CL/F 0.06±0.01 0.029±0.01 35.2 0.0015
4. tmax** 0.78 (0.83, 0.65) 0.64 (1.18, 0.41) 15.2 0.5358
5. Cmax 632.27±92.1 1831.36±1186.4 41.5 0.0483
6. Kel 1.24±0.01 1.52±0.01 15.4 0.2278
7. AUC (0−t) 1188.29±249.5 3461.74±2721.8 39.6 0.0897
8. AUC (0−∞) 1329.141±200.0 3520.644±2705.7 35.2 0.1006
9. AUMC 2067.691±377.1 5310.446±4612.2 28.7 0.149
10. MRT 1.55±0.11 1.417368±0.45 15.2 0.5324
*Expressed as harmonic mean with pseudo-standard deviation, **Expressed as median (minimum, maximum), p values in bold text represent statistically significant 
difference (obtained by paired samples t-test). C: Clopidogrel, EC: Esomeprazole+clopidogrel. V/F, CL/F: Volume of distribution and clearance are expressed as a 
function of bioavailability, AUC: Area under the curve, AUMC: Area under mean curve, MRT: Mean residence time
Table 5: Effect of esomeprazole on CPP pharmacokinetics in Sequence II participants
S.No. PK parameter Mean±SD %CV p value
Period 1EC Period 2C
1. t1/2ka* 0.36±0.19 0.54±0.03 14.8 0.3048
2. V/F 0.04±0.01 0.04±0.01 18.1 0.644
3. CL/F 0.03±0.01 0.05±0.01 30.5 0.1424
4. tmax 0.79 (1.40, 0.50) 0.78 (0.90, 0.76) 14.7 0.854
5. Cmax 982.66±209.3 702.43±154.9 17.2 0.0736
6. Kel 0.94±0.01 1.18±0.01 22.3 0.2773
7. AUC (0-t) 2234.32±718.2 1415.5±371.4 31.0 0.0868
8. AUC	(0-∞) 2438.34±715.6 1568.37±378.5 30.5 0.888
9. AUMC 5051.41±2730.0 2586.6±703.9 43.0 0.1127
10. MRT 1.93±0.65 1.63±0.10 15.0 0.3536
*Expressed as harmonic mean with pseudo-standard deviation, **expressed as median (minimum, maximum), p value in this table represent no statistically significant 
difference (p>0.05) represent statistically significant difference (obtained by paired samples t-test). C: Clopidogrel, EC: Esomeprazole+clopidogrel, AUC: Area under the 
curve, AUMC: Area under mean curve, MRT: Mean residence time, V/F, CL/F: Volume of distribution and clearance are expressed as a function of bioavailability
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Fig. 4: Inter-subject variability in period I
Fig. 5: Inter-subject variability in period II
variations in both primary and secondary parameters were observed 
during intra- and inter-subject variability analysis. Cmax of CPP was 
found to be increased by esomeprazole in both the sequences with a 
statistically	 significant	 increase	 in	 period	 II	 (ΔCmax=1199.09 pg/ml, 
p=0.0483). A transient increase in exposure to CPP with insignificant 
change in mean pharmacokinetic profile was observed on esomeprazole 
co-administration. Thus, systemic availability of AMC decreases and 
hence the exposure enhancing cardiovascular risks [32,33]. Significant 
alterations in clopidogrel V/F and CL/F observed in period II were not 
considered for further interpretation as such a difference was very 
negligible in period I. Hence change in clopidogrel V/F and CL/F could 
not be solely attributed to esomeprazole.
The magnitude of the studied interaction tends to be minor from our 
observations. Pharmacodynamic response to clopidogrel is largely 
affected by factors that decrease its bioavailability such as food, antacids 
and those that impair AMC production such as CYP450 allelic variations 
and enzyme inhibitors [34-37]. Although observed to be minor, severity 
of the interaction may be enhanced in patients with these underlying 
factors which decrease exposure to AMC. Hence, despite insignificant 
changes in pharmacokinetic profile, use of esomeprazole is not 
recommended in patients who are poor responders to clopidogrel so as 
to ensure adequate inhibition of platelet receptor activity.
CONCLUSION
The pharmacokinetic profile of CPP was found to be insignificantly 
altered by co-administration of esomeprazole. Minor changes in 
pharmacokinetic parameters observed could, however, be potentiated 
in the presence of underlying risk factors. Hence, concomitant 
administration of clopidogrel and esomeprazole should be under 
keen clinical supervision and is not recommended in poor responders 
to antiplatelet therapy with clopidogrel. The principal limitation 
of this study is that CPP concentrations were used as an indirect 
measure of AMC pharmacokinetics due to practical difficulties in AMC 
quantification. In spite of being previously reported, the reliability of 
such an assumption is often questionable as AMC concentrations may 
not merely have inverse relationships with that of CPP. Hence, further 
studies are necessary to study this interaction with direct AMC profiling 
with pharmacodynamic response monitoring.
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